IMP-731 is under clinical development by Immutep and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase I drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMP-731’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMP-731 overview
GSK-2831781 is under development for the treatment of ulcerative colitis, and autoimmune diseases such as chronic plaque-type psoriasis. It is administered via intravenous and subcutaneous route as a solution. The drug candidate is a humanized antibody dependent cell cytotoxicity (ADCC) enhanced monoclonal afucosylated antibody derived from IMP731 and which is specific to the cells expressing Lymphocyte Activation Gene-3 (LAG-3) protein.
Immutep overview
Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company partners with pharmaceutical and biotech companies for research and development activities. It has operations across Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.
For a complete picture of IMP-731’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
